This study investigated the prevalence and impact of monogenic FH and clinically defined FH in a large proportion of the Icelandic population.
This study investigated the duration of pregnancy-related off-statin periods in Norwegian and Dutch women with FH. Among these women, 86% wanted to receive more information on pregnancy and breastfeeding in relation to FH.
The US Food and Drug Administration (FDA) approved evolocumab as treatment for pediatric patients with heterozygous FH of 10 years and older to reduce LDL-c levels.
The EAS FHSC have created a global registry of FH patients for the surveillance of FH worldwide. Findings of the present study on the adult population show that FH is diagnosed late and LDL-c targets are often not achieved.
ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.
Physician reminders for recommended LLT led to an increase in the proportion of patients with FH and/or CVD achieving LDL-c treatment goals. However, treatment inertia exists in patients with FH, including those with established CVD.
Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.
EAS 2021 This study showed that children with familiar hypercholesterolemia had an increased susceptibility of LDL particles to form aggregates and a reduced cholesterol efflux capacity of HDL compared to healthy children.
EAS 2021 An interim-analysis of the HEYMANS study showed that the majority of FH (both HeFH and HoFH) patients have a history of CV events and comorbidities. Initiation of evolocumab in these patients resulted in reduced LDL-c levels, maintained throughout the study.
Heterozygous LDLR gene mutations were most prevalent when screening for autosomal dominant hypercholesterolemia in hypercholesterolemia patients and relatives from Norway.
This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.
The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.